DREXEL UNIVERSITY Polypharmacy, commonly defined as taking five or more medications daily, is a significant health care concern impacting over 30% of older adults. It is associated with poor health outcomes like falls, medication interactions, hospitalizations and even death. Older adults are at an increased risk of experiencing polypharmacy if they have multiple chronic conditions. While older...
Category: <span>Alzheimer’s</span>
Post
Alzheimer’s research: Superspreader fibrils caught in the act
by Andrea Six, Swiss Federal Laboratories for Materials Science and Technology Suspicious protein molecules and fibrils aggregate on nerve cells in dementia. Credit: Empa The treatment of dementia disorders such as Alzheimer’s is still one of the greatest challenges facing modern medicine. In the course of neurodegenerative diseases, certain proteins such as the amyloid β protein...
Post
More Evidence Ties Semaglutide to Reduced Alzheimer’s Risk
A new study provides real-world evidence to support the potential repurposing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), used to treat type 2 diabetes and obesity, for prevention of Alzheimer’s disease (AD). Adults with type 2 diabetes who were prescribed the GLP-1 RA semaglutide had a significantly lower risk for AD compared with their peers who were prescribed any of...
Post
Popular diabetes and weight-loss drug may reduce risk of Alzheimer’s disease
by Case Western Reserve University Credit: SHVETS production from Pexels Researchers at the Case Western Reserve School of Medicine have found that when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer’s disease in people with type 2 diabetes (T2D). Alzheimer’s disease is a brain disorder...
Post
New insights into amyloid β fibril growth offer hope for halting Alzheimer’s progression
by National Institute for Physiological Sciences The process of alternating elongation and pausing of amyloid β (Aβ) fibrils was captured by combining high-speed atomic force microscopy (HS-AFM) and Monte Carlo simulations. The study revealed the mechanism by which the 4396C antibody selectively binds to the “paused state” of fibril growth, effectively inhibiting further elongation of...
Post
Alzheimer’s disease may damage the brain in two phases
SEA-AD study of the MTG and cohort description. Credit: Nature Neuroscience (2024). DOI: 10.1038/s41593-024-01774-5 Alzheimer’s disease may damage the brain in two distinct phases, based on new research using sophisticated brain mapping tools. According to researchers who discovered this new view, the first, early phase happens slowly and silently—before people experience memory problems—harming just a few vulnerable...
Post
Could a once-daily pill for seizures also treat Alzheimer’s disease?
A once-a-day pill used to treat seizures could also help treat Alzheimer’s disease, a new study suggests. Image credit: Viktoriya Skorikova/Getty Images. Past research shows that for many people, mild cognitive impairmentTrusted Source can be the first sign of Alzheimer’s disease. About one-third of people who have mild cognitive impairment because of Alzheimer’s disease progresses to dementia within 5 years. “Our studies...
Post
New brain cell cleaner: astrocytes raise possibility of Alzheimer’s disease treatment
Autophagy plasticity in astrocytes enhances the removal of dementia-causing substances and the potential for brain function recovery. Astrocytes, non-neuronal cells, are a new target for Alzheimer’s disease (AD) treatment Peer-Reviewed PublicationNational Research Council of Science & Technology The mechanism of astrocytic autophagy plasticity plays a crucial role in AD. When the autophagy-regulating genes (LC3B and...
Post
Researchers close in on understanding possible cause of Alzheimer’s disease
News Release 30-Sep-2024 Awarded four-year, $3.3M grant from National Institutes of Health Grant and Award AnnouncementCase Western Reserve University Matthias Buck, professor of physiology and biophysics view moreCredit: Case Western Reserve University CLEVELAND—With a four-year, $3.3 million grant from the National Institutes of Health (NIH), researchers from Case Western Reserve University will study whether certain...
Post
Synthetic THC may calm agitation in Alzheimer’s patients
September 30, 2024 by Carole Tanzer Miller A synthetic form of the active ingredient in cannabis helps reduce agitation in people with Alzheimer’s, new research shows. Synthetic THC (dronabinol) also gave patients’ caregivers a boost, according to findings presented at a meeting of the International Psychogeriatrics Association in Buenos Aires. The findings may provide encouragement...